

	September 30, 2019
	Carrying Value		Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(In millions)
Fixed maturity securities available for sale:
Corporate debt securities	$	18.7	$	19.3	$	0.8	$	(1.4	)	$	18.7
Total	$	18.7	$	19.3	$	0.8	$	(1.4	)	$	18.7



	December 31, 2018
	Carrying Value		Cost Basis		Unrealized Gains		Unrealized Losses			Fair Value
	(In millions)
Fixed maturity securities available for sale:
Corporate debt securities	$	17.8	$	18.8	$	0.9	$	(1.9	)	$	17.8
Total	$	17.8	$	18.8	$	0.9	$	(1.9	)	$	17.8

The cost basis of fixed maturity securities available for sale includes an adjustment for amortized premium or discount and other-than-temporary-impairment recognized in earnings since the date of purchase.

As of September 30, 2019 the fixed maturity securities in our investment portfolio had a maturity of greater than one year but less than five years. Expected maturities may differ from contractual maturities because certain borrowers have the right to call or prepay obligations with or without call or prepayment penalties.

Net unrealized losses on investment securities and the fair value of the related securities, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2019 and December 31, 2018 were as follows (in millions):

During the nine months ended September 30, 2019, the three months ended September 30, 2018, and the nine months ended September 30, 2018 we incurred $0.4 million, $9.5 million and $9.5 million, respectively, of other-than-temporary impairment charges relating to corporate debt securities which is included in Realized gains, net on the Condensed Consolidated Statements of Operations. The impairment recorded relates to corporate debt holdings of one investee which have experienced a prolonged period of declining earnings and which we are uncertain of our ability to recover our initial investment. All of the loss represents credit loss recognized in earnings and no portion of the loss was included in other comprehensive earnings. During the three months ended September 30, 2019 we incurred no other-than-temporary impairment charges relating to investment securities.

As of September 30, 2019, we held corporate debt securities with a fair value of $2.2 million for which an other-than-temporary impairment had been previously recognized. It is possible that future events may lead us to recognize potential future impairment losses related to our investment portfolio and that unanticipated future events may lead us to dispose of certain investment holdings and recognize the effects of any market movements in our results of operations.

Investments in unconsolidated affiliates recorded using the equity method of accounting as of September 30, 2019 and December 31, 2018 consisted of the following (in millions):



	Ownership at September 30, 2019		September 30, 2019		December 31, 2018
Ceridian	20.0	%	$	370.3	$	359.7
Dun & Bradstreet	24.3	%	446.2		—
Other	various		35.4		37.5
Total			$	851.9	$	397.2

Equity in earnings (losses) of unconsolidated affiliates for the three and nine months ended September 30, 2019 and September 30, 2018 consisted of the following (in millions):



	Three months ended September 30, 2019			Three months ended September 30, 2018		Nine months ended September 30, 2019			Nine months ended September 30, 2018
Ceridian	$	12.7		$	1.2	$	16.7		$	(20.4	)
Dun & Bradstreet	(21.4		)	—		(68.6		)	—
Other	0.4			2.6		1.1			3.5
Total	$	(8.3	)	$	3.8	$	(50.8	)	$	(16.9	)

Summarized financial information for Ceridian for the relevant dates and time periods included in Investments in unconsolidated affiliates and Equity in earnings (losses) of unconsolidated affiliates in our Condensed Consolidated Balance Sheets and Statements of Operations, respectively, is presented below. LifeWorks Corporation Ltd. ("LifeWorks"), a former subsidiary of Ceridian, was distributed pro-rata to Ceridian shareholders contemporaneously with Ceridian's initial public offering in April 2018. On July 27, 2018, LifeWorks was sold. The results of Ceridian for the three and nine months ended September 30, 2018 have been adjusted to remove the effects of the discontinued operations of LifeWorks as well as to reflect Ceridian's retrospective adoption of ASC Topic 606 and certain other accounting standards.



	September 30, 2019		December 31, 2018
	(In millions)
Total current assets before customer funds	$	400.3	$	330.6
Customer funds	2,604.0		2,603.5
Goodwill and other intangible assets, net	2,142.9		2,114.9
Other assets	289.0		198.8
Total assets	$	5,436.2	$	5,247.8
Current liabilities before customer obligations	$	152.8	$	149.9
Customer obligations	2,590.4		2,619.7
Long-term obligations, less current portion	659.3		663.5
Other long-term liabilities	180.6		199.2
Total liabilities	3,583.1		3,632.3
Equity	1,853.1		1,615.5
Total liabilities and equity	$	5,436.2	$	5,247.8



	Three months ended September 30, 2019			Three months ended September 30, 2018		Nine months ended September 30, 2019		Nine months ended September 30, 2018
	(In millions)					(In millions)
Total revenues	$	202.3		$	178.1	$	602.3	$	545.9
(Loss) earnings before income taxes	(2.9		)	6.5		22.7		(37.9		)
Earnings (loss) before discontinued operations	62.7			7.2		80.2		(44.2		)
Net earnings (loss) attributable to Ceridian	62.7			4.2		80.2		(58.5		)

On February 8, 2019, we closed on our previously announced acquisition of DNB (the "DNB Acquisition"). The DNB Acquisition was financed through a combination of $2.1 billion of common equity financing provided to DNB's ultimate parent and acquirer Star Parent, L.P. ("Star") by a consortium of investors including Cannae and various other investors, $1.1 billion of preferred equity in a wholly-owned subsidiary of Star from various sources and $4.0 billion of debt financing from various lenders. The proceeds were used by Star and its subsidiaries to purchase DNB (collectively with Star and its subsidiaries, "Dun & Bradstreet") .

Of our previously disclosed $900.0 million commitment to purchase common equity of Star, we retained and funded a $505.6 million investment (the "Dun & Bradstreet Investment"), representing 24.5% of the outstanding common equity of Dun & Bradstreet, and syndicated the remainder to other investors. We funded the Dun & Bradstreet Investment through a combination of cash on hand and borrowings on the Margin Loan and FNF Revolver (each, as defined below in Note F). On the closing date, we recorded income of $9.1 million for syndication fees from DNB which is recorded in Other income in our Condensed Consolidated Statement of Operations for the nine months ended September 30, 2019. We also recorded a reduction in our investment of $2.9 million for our ratable portion of the syndication fees capitalized as equity issuance costs by Dun & Bradstreet.

In April and August 2019, we syndicated an additional $2.6 million and $0.5 million, respectively, of our Dun & Bradstreet Investment to other investors. The syndications resulted in a reduction in the Company's ownership to 24.3% of the outstanding common equity of Dun & Bradstreet.

On June 27, 2019, we made an additional pro-rata investment of $23.5 million in Dun & Bradstreet. Dun & Bradstreet used the proceeds to partially fund its acquisition of Lattice (see Note A).

Summarized financial information for Dun & Bradstreet for the relevant dates and time periods included in Investments in unconsolidated affiliates and Equity in earnings (losses) of unconsolidated affiliates in our Condensed Consolidated Balance Sheets and Statements of Operations, respectively, is presented below.

We historically reported our equity in earnings or loss of Dun & Bradstreet on a one quarter lag. In the third quarter of 2019 we began receiving financial information from Dun & Bradstreet timely and recording our equity in its losses on a real-time basis. Accordingly, our net earnings for the three and nine month periods ended September 30, 2019, include the Company’s equity in Dun & Bradstreet’s losses for the period from July 1, 2019 through September 30, 2019 and February 8, 2019 through September 30, 2019, respectively. See Note A for further information on the impact of the change in accounting principle.



	September 30, 2019
	(In millions)
Total current assets	$	373.1
Goodwill and other intangible assets, net	8,221.4
Other assets	481.2
Total assets	$	9,075.7

Current liabilities	$	833.3
Long-term debt	3,839.6
Other non-current liabilities	1,498.3
Total liabilities	6,171.2
Preferred equity	1,028.4
Total capital	1,876.1
Total liabilities and equity	$	9,075.7



	Three months ended September 30, 2019			Period from February 8, 2019 to September 30, 2019
	(In millions)
Total revenues	$	408.2		$	981.2
Loss before income taxes	(79.2		)	(277.1		)
Net loss	(54.9		)	(196.5		)
Dividends attributable to preferred equity and noncontrolling interest expense	(33.5		)	(85.3		)
Net loss attributable to Dun & Bradstreet	(88.4		)	(281.8		)

We account for our investment in QOMPLX at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly market transactions. As of September 30, 2019, we have $15.0 million recorded for our investment in QOMPLX which is included in Other long term investments and noncurrent assets on our Condensed Consolidated Balance Sheet. We have not recorded any upward or downward adjustments to our investment in QOMPLX.